Last updated on July 2020

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Brief description of study

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA) in combination (Combination 3) in participants with metastatic castration-resistant prostate cancer (mCRPC).

Detailed Study Description

This multicenter study will evaluate safety and efficacy of niraparib in combination with other anti-cancer agents. Combination 1 will combine niraparib with the anti-programmed cell death protein (PD)-1 monoclonal antibody cetrelimab, in participants with mCRPC. Combination 1 has 2 parts: in Part 1 (dose selection), participants will be enrolled to establish RP2D doses of niraparib and cetrelimab; and Part 2 (dose expansion) will evaluate the combination therapy in an expanded number of participants into 2 cohorts (biomarker positive or biomarker negative). Combination 2 is closed to enrollment. Combination 3 will evaluate the relative bioavailability (BA) of niraparib and AA in combination. In pharmacokinetics (PK) assessment phase niraparib will be administered in combination with AA and in extension phase niraparib plus AA will be administered in combination with prednisone. Combinations 1 and 2 will have 4 phases: A Pre-screening Phase, a Screening Phase, a Treatment Phase, and a Follow-up Phase; Combination 3 has 3 phases: A Screening Phase, A PK Assessment Phase, and an Extension Phase. Study evaluations will include efficacy, PK, PK/pharmacodynamics, biomarkers, safety and tolerability.

Clinical Study Identifier: NCT03431350

Find a site near you

Start Over

Massachusetts General

Boston, MA United States
  Connect »

Thomas Jefferson University

Philadelphia, PA United States
  Connect »

MUSC-Hollings Cancer Center

Charleston, SC United States
  Connect »

Carolina Urologic Research Center

Myrtle Beach, SC United States
  Connect »

Utah Cancer Specialists

Salt Lake City, UT United States
  Connect »

Urology of Virginia, PLCC

Virginia Beach, VA United States
  Connect »

ZNA Middelheim

Antwerpen, Belgium
  Connect »

Az Groeninge

Kortrijk, Belgium
  Connect »

Guy's Hospital

London, United Kingdom
  Connect »

Southampton General Hospital

Southampton, United Kingdom
  Connect »

University of Florida

Jacksonville, FL United States
  Connect »

Intermountain Healthcare

Saint George, UT United States
  Connect »

Florida Hospital

Orlando, FL United States
  Connect »

First Urology, PSC

Jeffersonville, IN United States
  Connect »

Houston Metro Urology

Houston, TX United States
  Connect »

Soroka Hospital

Beer-Sheva, Israel
  Connect »

Urology Centers Of Alabama

Homewood, AL United States
  Connect »

Mayo Clinic Arizona

Phoenix, AZ United States
  Connect »

Clinical Research Solutions, LLC

Middleburg Heights, OH United States
  Connect »

Oregon Urology Institute

Springfield, OR United States
  Connect »

Urologic Consultants of SE PA

Bala-Cynwyd, PA United States
  Connect »

Urology Associates

Nashville, TN United States
  Connect »

Centre Hospitalier Lyon Sud

Pierre Benite Cedex, France
  Connect »

HIA Begin

Saint Mande, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.